<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>sdü tıp fak derg</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Medical Journal of Süleyman Demirel University</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2602-2109</issn>
                                                                                            <publisher>
                    <publisher-name>Süleyman Demirel Üniversitesi</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.17343/sdutfd.363352</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Clinical Sciences</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Klinik Tıp Bilimleri</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <article-title>Detection of Anti-HLA Antibodies Produced After Transplantation in Renal Transplants and Evaluation of Its Association with the Other Parameters</article-title>
                                                                                                                                                                                                <trans-title-group xml:lang="tr">
                                    <trans-title>Böbrek Nakli Olan Hastalarda Nakil Sonrasında Oluşan Anti-HLA Antikorlarının Saptanması ve Çeşitli Parametrelerle İlişkisinin Değerlendirilmesi</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                <name>
                                    <surname>Özkızılcık Koçyiğit</surname>
                                    <given-names>Aslı</given-names>
                                </name>
                                                                    <aff>İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Pirim</surname>
                                    <given-names>İbrahim</given-names>
                                </name>
                                                                    <aff>İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Kılıçaslan Ayna</surname>
                                    <given-names>Tülay</given-names>
                                </name>
                                                                    <aff>İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Soyöz</surname>
                                    <given-names>Mustafa</given-names>
                                </name>
                                                                    <aff>İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20181201">
                    <day>12</day>
                    <month>01</month>
                    <year>2018</year>
                </pub-date>
                                        <volume>25</volume>
                                        <issue>4</issue>
                                        <fpage>385</fpage>
                                        <lpage>392</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20171207">
                        <day>12</day>
                        <month>07</month>
                        <year>2017</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20180312">
                        <day>03</day>
                        <month>12</month>
                        <year>2018</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi</copyright-statement>
                    <copyright-year>1994</copyright-year>
                    <copyright-holder>Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>Aim: In this study,it was aimed to evaluate the immunological response to graft and itsassociation with related factors in the sera samples collected periodicallyfrom patients transplanted from deceased or alive donors in Izmir TepecikEducation and Research Hospital.Material and Method: Anti-HLAantibody screening and identification tests of 31 patient sera samples wereperformed by flow cytometric method. The sera samples were collectedperiodically (1st day, 1st week, 2nd week, 4thweek, 12th week, 24th week and 52nd week)after transplantations in our hospital. After the screening of all samples, anti-HLAantibodies of PRA positive samples were identified. All of procedures were performedaccording to the manufacturer’s instructions. The other parameters were statisticallyevaluated by Pearson correlation test.Results: Of thepatients, 12.9% and 6.45% were only class I and II positive in thepost-transplant 52nd week, respectively. None of the patients wasclass I and II positive. It was found that antibodies were not produced againstmismatched antigens on the 1st day, 1st, 2nd, 4th, and 12thweeks after transplantation. The antibodies were produced 24 weeks aftertransplantation in some cases. However, the results could not be evaluatedstatistically because of the small patient group. There were statisticallysignificant correlations between last creatinine levels-donor ages and GFRvalues-patient ages (p&amp;lt;0.001, p&amp;lt;0.01, respectively), whereas there was nosignificant association between antibody production and creatinine levels. Conclusion: It wasobserved that anti-HLA antibodies were produced before transplantation in apatient with pre-transplant blood transfusion. The antibodies were produced in24th week in five patients. Therefore, anti-HLA antibody screeningtests to be performed on the 12th week after transplantation may be importantfor the treatment protocol.</p></abstract>
                                                                                                                                    <trans-abstract xml:lang="tr">
                            <p>Amaç: Bu çalışmada İzmirTepecik Eğitim ve Araştırma Hastanesi’nde kadavra veya canlı donörden böbreknakli olmuş hastaların nakil sonrasında periyodik olarak toplanan serumörneklerinde grefte karşı gelişen immünolojik cevabın ve ilgili faktörlerlearasındaki ilişkisinin değerlendirilmesi amaçlanmıştır.Gereç ve Yöntem: 31hasta serumunun anti-HLA antikor tarama ve tanımlama testleri flow sitometrikyöntemle yapılmıştır. Bu serum örnekleri, hastanemizde nakilden sonra periyodikolarak (1. gün, 1. hafta, 2. hafta, 4. hafta, 12. hafta, 24. hafta ve 52.hafta) toplanmıştır. Bütün örneklere tarama testi yapılırken, sadece PRApozitif olan serum örneklerine anti-HLA antikor tipini belirlemek amacıylatanımlama testi uygulanmıştır. Bütün prosedürler üretici firmanın talimatlarınagöre yapılmıştır. Diğer parametreler Pearson korelasyon testiyle istatistikseloalrak değerlendirilmiştir. Bulgular: Nakilden sonra52. haftadan sonra hastaların sırasıyla %12,9 ile %6,45’i anti-HLA sınıf I veII antikorları bakımından pozitif bulunmuştur. Hastalarda 1. gün, 1., 2., 4. ve12. haftalarda mismatch antijenlere karşı antikor oluşumu gözlenmemiştir. Birhastada antikorlar 24. haftadan itibaren oluşmuştur. Yapılan korelasyonanalizlerinde hastaların nakil sonrası son kreatinin değerleriyle donör yaşlarıve GFR değerleriyle hasta yaşları arasında istatistiksel olarak anlamlısonuçlar elde edilmiştir (sırasıyla p&amp;lt;0.001, p&amp;lt;0.01). Nakil sonrasında denovo antikor üreten hastaların kreatinin değerleriyle antikor üretimi arasındailişki bulunmamıştır (p&amp;gt;0.05). Sonuç: Nakil öncesindekan transfüzyonu olan bir hastada 12. haftada anti-HLA antikoru oluştuğugörülmüştür. 5 hastada 24. haftadan sonra antikor oluşmuştur. Dolayısıyla nakilsonrası 12. haftadan itibaren rutinde yapılacak anti-HLA antikoru taramatestleri tedavi protokolü için önemli olabilir.</p></trans-abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>kidney transplantation</kwd>
                                                    <kwd>  histocompatibility</kwd>
                                                    <kwd>  HLA</kwd>
                                            </kwd-group>
                                                        
                                                                            <kwd-group xml:lang="tr">
                                                    <kwd>böbrek nakli</kwd>
                                                    <kwd>  doku uyumu</kwd>
                                                    <kwd>  HLA</kwd>
                                            </kwd-group>
                                                                                                            </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol 2013;74(5): 666-672.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">McMurtrey C, Lowe D, Buchli R, Daga S, Royer D, Humphrey A, et al. Profiling antibodies to class II HLA in transplant patient sera. Hum Immunol 2014; 75(3): 261-270.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">Ishida H, Hirai T, Kohei N, Yamaguchi Y, Tanabe K. Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation. Transplant Int 2011; 24(2): 150-7.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">Ayna TK, Çalışkan Y, Çiftçi HŞ, Türkmen A, Gürtekin M. Long-term Effects of Antibodies Against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation. Balkan Med J 2013;30(1): 37-45.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">Kurtulmuş Y, Ayna TK, Soyöz M, Özyılmaz B, Tanrısev M, Afacan G, et al. Comparison of Anti-HLA Antibodies of Kidney Transplant Candidates with Chronic Renal Failure by Two Different Methods: Flow-PRA and Luminex PRA. Transplant Proceed 2013;45(3): 875-877.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">Pirim I, Soyoz M, Ayna TK, Kocyigit AO, Gurbuz BC, Tugmen C, et al. De novo Produced Anti-Human Leukocyte Antigen Antibodies Relation to Alloimmunity in Patients with Chronic Renal Failure. Genet Test Mol Biomarkers 2015; 19(6): 335-8.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">Açıkgöz HE, Tüysüz Ö, Sarandöl E, Dirican M. [Comparison of MDRD Formula and Creatinine Clearance in Estimation of Glomerular Filtration Rate]. Tr Biokim Derg 2013;11(1): 21-29.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">Coronel F, Sanchez-Fructuoso A, Conesa J, Prats D, Barrientos A. Pre-Transplant Treatment Modality and Renal Transplant Outcomes. Dial Transplant 2006;35(8): 1-4.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">Jordan SC and Vo AA. Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant 2014;19(6): 591-597.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">Zhang Q, Liang LW, Gjertson DW, Lassman C, Wilkinson AH, Kendrick E, et al. Development of Posttransplant Antidonor HLA Antibodies Is Associated with Acute Humoral Rejection and Early Graft Dysfunction. Transplantation 2005;79(5): 591–598.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">Cardarelli F, Pascual M, Tolkoff-Rubin N, Deşmonico FL, Wong W, Schoenfeld DA et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005;18(5): 532–540.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">Takemoto S, Port FK, Claas FHJ, Duquesnoy RJ. HLA Matching for Kidney Transplantation. Hum Immunol 2004;65(12): 1489 –1505.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">Imamovic S, Ljuca F, Imamovic G, Iljazagic Halilovic F, Krdzalic A, Hasukic S, et al. Influence of Donor Age on Renal Graft Function in the first Seven Post Transplant Days. Bosnian J Basic Med 2010;10(1): 73-77.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">Baptista APM, Junior HTS, Pestana JOM. Influence of deceased donor hemodynamic factors in transplant recipient renal function. J Bras Nephrol 2013;35(4): 289-298.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">Lim WH, Chapman JR, Coates PT, Lewis JR, Russ GR, Watson N, et al. HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2016;11(5):875-883.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">Hajeer AH. Panel Reactive Antibody test (PRA) in renal transplantation. Saudi J Kidney Dis Transpl 2006;17(1):1-4.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
